A randomised controlled trial to investigate the clinical effectiveness and cost effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) for depressed non-responders to Increasing Access to Psychological Therapies (IAPT) high-intensity therapies: study protocol

被引:2
作者
Barnhofer, Thorsten [1 ]
Dunn, Barnaby D. D. [2 ]
Strauss, Clara [3 ]
Ruths, Florian [4 ]
Barrett, Barbara [5 ]
Ryan, Mary [6 ,7 ]
Ladwa, Asha [2 ]
Stafford, Frances [3 ]
Fichera, Roberta [4 ]
Baber, Hannah [8 ]
McGuinness, Ailis [2 ]
Metcalfe, Isabella [4 ]
Harding, Delilah [4 ]
Walker, Sarah [8 ]
Ganguli, Poushali [5 ]
Rhodes, Shelley [8 ]
Young, Allan [9 ]
Warren, Fiona [8 ]
机构
[1] Univ Surrey, Sch Psychol, Guildford, England
[2] Univ Exeter, Dept Psychol, Exeter, England
[3] Univ Sussex, Brighton, England
[4] South London & Maudsley NHS Fdn Trust, London, England
[5] Kings Coll London, Kings Hlth Econ, London, England
[6] Southbank Univ, Dept Hlth, London, England
[7] Southbank Univ, Social Care Innovat Lab, London, England
[8] Univ Exeter, Coll Med & Hlth, Exeter, England
[9] Kings Coll London, Ctr Affect Disorders, London, England
基金
美国国家卫生研究院;
关键词
Mindfulness-Based Cognitive Therapy; Major depressive disorder; Treatment non-response; Increasing Access for Psychological Therapies (IAPT); HEALTH; VALIDATION; DISORDER; ADHERENCE; SYMPTOMS; OUTCOMES; RELAPSE; SCALE; PHQ-9; CARE;
D O I
10.1186/s13063-022-06882-w
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundMajor depression represents a pressing challenge for health care. In England, Increasing Access to Psychological Therapies (IAPT) services provide evidence-based psychological therapies in a stepped-care approach to patients with depression. While introduction of these services has successfully increased access to therapy, estimates suggest that about 50% of depressed patients who have come to the end of the IAPT pathway still show significant levels of symptoms. This study will investigate whether Mindfulness-Based Cognitive Therapy (MBCT), a group intervention combining training in mindfulness meditation and elements from cognitive therapy, can have beneficial effects in depressed patients who have not responded to high-intensity therapy in IAPT. It will seek to establish the effectiveness and cost-effectiveness of MBCT as compared to the treatment these patients would usually receive.MethodsIn a 2-arm randomised controlled trial, patients who currently meet the criteria for major depressive disorder and who have not sufficiently responded to at least 12 sessions of IAPT high-intensity therapy will be allocated, at a ratio of 1:1, to receive either MBCT (in addition to treatment as usual [TAU]) or continue with TAU only. Assessments will take place at baseline, 10 weeks and 34 weeks post-randomisation. The primary outcome will be reduction in depression symptomatology 34 weeks post-randomisation as assessed using the Public Health Questionnaire-9 (PHQ-9). Secondary outcomes will include depressive symptomatology at 10 weeks post-randomisation and other clinical outcomes measured at 10-week and 34-week follow-up, along with a series of binarised outcomes to indicate clinically significant and reliable change. Evaluations of cost-effectiveness will be based on assessments of service use costs collected using the Adult Service Use Schedule and health utilities derived from the EQ-5D.DiscussionThis trial will add to the evidence base for the use of MBCT in depressed treatment non-responders. It will constitute the first trial to test MBCT following non-response to psychological therapy, with results providing a direct estimate of efficacy within the IAPT pathway. As such, its results will offer an important basis for decisions regarding the adoption of MBCT for non-responders within IAPT.
引用
收藏
页数:18
相关论文
共 43 条
  • [21] Data sharing in clinical trials - practical guidance on anonymising trial datasets
    Keerie, Catriona
    Tuck, Christopher
    Milne, Garry
    Eldridge, Sandra
    Wright, Neil
    Lewis, Steff C.
    [J]. TRIALS, 2018, 19
  • [22] The PHQ-9 - Validity of a brief depression severity measure
    Kroenke, K
    Spitzer, RL
    Williams, JBW
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2001, 16 (09) : 606 - 613
  • [23] Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial
    Kuyken, Willem
    Hayes, Rachel
    Barrett, Barbara
    Byng, Richard
    Dalgleish, Tim
    Kessler, David
    Lewis, Glyn
    Watkins, Edward
    Brejcha, Claire
    Cardy, Jessica
    Causley, Aaron
    Cowderoy, Suzanne
    Evans, Alison
    Gradinger, Felix
    Kaur, Surinder
    Lanham, Paul
    Morant, Nicola
    Richards, Jonathan
    Shah, Pooja
    Sutton, Harry
    Vicary, Rachael
    Weaver, Alice
    Wilks, Jenny
    Williams, Matthew
    Taylor, Rod S.
    Byford, Sarah
    [J]. LANCET, 2015, 386 (9988) : 63 - 73
  • [24] Health policy - The case for psychological treatment centres
    Layard, R
    [J]. BRITISH MEDICAL JOURNAL, 2006, 332 (7548): : 1030 - 1032
  • [25] Monitoring depression treatment outcomes with the patient health questionnaire-9
    Löwe, B
    Unützer, J
    Callahan, CM
    Perkins, AJ
    Kroenke, K
    [J]. MEDICAL CARE, 2004, 42 (12) : 1194 - 1201
  • [26] McManus S., 2016, MENTAL HLTH WELLBEIN
  • [27] Defining successful treatment outcome in depression using the PHQ-9: A comparison of methods
    McMillan, Dean
    Gilbody, Simon
    Richards, David
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2010, 127 (1-3) : 122 - 129
  • [28] Effect of Telephone-Administered vs Face-to-face Cognitive Behavioral Therapy on Adherence to Therapy and Depression Outcomes Among Primary Care Patients A Randomized Trial
    Mohr, David C.
    Ho, Joyce
    Duffecy, Jenna
    Reifler, Douglas
    Sokol, Leslie
    Burns, Michelle Nicole
    Jin, Ling
    Siddique, Juned
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (21): : 2278 - 2285
  • [29] The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications
    Moylan, S.
    Maes, M.
    Wray, N. R.
    Berk, M.
    [J]. MOLECULAR PSYCHIATRY, 2013, 18 (05) : 595 - 606
  • [30] NHS Community & Mental Health Team, 2021, PSYCH THER ANN REP U